Answers are grounded in this paper and cite their sources.
Many incurable mitochondrial disorders result from mutant mitochondrial DNA (mtDNA) and impaired respiration. Leigh's syndrome (LS) is a fatal neurodegenerative disorder of infants, and Leber's hereditary optic neuropathy (LHON) causes blindness in young adults. Treatment of LHON and LS cells harboring G11778A and T8993G mutant mtDNA, respectively, by >90%, with healthy donor mtDNA complexed with recombinant human mitochondrial transcription factor A (rhTFAM), improved mitochondrial respiration by ∼1.2-fold in LHON cells and restored >50% ATP synthase function in LS cells. Mitochondrial replication, transcription, and translation of key respiratory genes and proteins were increased in the short term. Increased NRF1, TFAMB1, and TFAMA expression alluded to the activation of mitochondrial biogenesis as a mechanism for improving mitochondrial respiration. These results represent the development of a therapeutic approach for LHON and LS patients in the near future. Iyer and colleagues use healthy mitochondrial DNA (mtDNA) complexed with a recombinant human mitochondrial transcription factor A protein as a platform for gene delivery to mitochondria. Using this approach, they are able to introduce healthy mtDNA into cytoplasmic hybrid (cybrid) cells containing platelets from a human subject with Leber's hereditary optic neuropathy and, subsequently, into primary skin fibroblasts from a human subject with Leigh's syndrome.
No takes yet. Share an insight, caveat, or question.
Iyer et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: